Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Early treatment with heart failure drugs lisinopril and spironolactone improves skeletal muscle pathology in Duchenne muscular dystrophy (DMD) mouse models. The angiotensin converting enzyme inhibitor lisinopril and mineralocorticoid receptor (MR) antagonist spironolactone indirectly and directly target MR. The presence and function of MR in skeletal muscle have not been explored. MR mRNA and protein are present in all tested skeletal muscles from both wild‐type mice and DMD mouse models. MR expression is cell autonomous in both undifferentiated myoblasts and differentiated myotubes from mouse and human skeletal muscle cultures. To test for MR function in skeletal muscle, global gene expression analysis was conducted on human myotubes treated with MR agonist (aldosterone; EC50 1.3 nM) or antagonist (spironolactone; IC50 1.6 nM), and 53 gene expression differences were identified. Five differences were conserved in quadriceps muscles from dystrophic mice treated with spironolactone plus lisinopril (IC 50 0.1 nM) compared with untreated controls. Genes down‐regulated more than 2‐fold by MR antagonism included FOS, ANKRD1 , and GADD45B , with known roles in skeletal muscle, in addition to NPR3 and SERPINA3, bona fide targets of MR in other tissues. MR is a novel drug target in skeletal muscle and use of clinically safe antagonists may be beneficial for muscle diseases.— Chadwick, J. A., Hauck, J. S., Lowe, J., Shaw, J. J., Guttridge, D. C., Gomez‐Sanchez, C. E., Gomez‐Sanchez, E. P., Rafael‐Fortney, J. A. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J. 29, 4544‐4554 (2015). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
X chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765 · cited 1×
“For this study, we used tissue from several DMD mouse models: dystrophin-deficient mdx mice (27, 28), het mice (8), and dystrophin/utrophin-deficient double knockout (dko) mice (29), in addition to 10(J)/10J (JAX 00665; The JacksonLaboratory, BarHarbor,ME,USA)wild-type control mice.”
MethodEmery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
Utrophin–dystrophin-deficient mice as a model for Duchenne muscular dystrophy
Deconinck, A. E., Rafael, J. A., Skinner, J. A., Brown, S. C., Potter, A. C., Metzinger, L., Watt, D. J., Dickson, J. G., Tinsley, J. M., & Davies, K. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80532-2 · Cited by 752
Lastra, G., Whaley-Connell, A., Manrique, C., Habibi, J., Gutweiler, A. A., Appesh, L., Hayden, M. R., Wei, Y., Ferrario, C., & Sowers, J. R. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00258.2007 · Cited by 119 · cited 1×
“One study has shown spironolactone is able to improve insulin-stimulated glucose transport in skeletal muscle by reducing reactive oxygen species in rats overexpressing renin, but a direct effect on skeletal muscle cells was not investigated (24).”
BackgroundLannan, E. A., Galliher-Beckley, A. J., Scoltock, A. B., & Cidlowski, J. A. (2012) · Endocrinology · doi:10.1210/en.2012-1020 · Cited by 91 · cited 1×
“Glucocorticoid treatment of lung cells led to increased SERPINA3 expression, which was postulated to cause some of the adverse effects seen with long-term glucocorticoid therapy (45).”
Background
Cited by
Heart Failure Stimulates Tumor Growth by Circulating Factors
Meijers, W. C., Maglione, M., Bakker, S. J. L., Oberhuber, R., Kieneker, L. M., de Jong, S., Haubner, B. J., Nagengast, W. B., Lyon, A. R., van der Vegt, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030816 · Cited by 385
Potassium homeostasis: sensors, mediators, and targets
McDonough, A. A., & Fenton, R. A. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02718-3 · Cited by 61
“Evidence for physiologically relevant activity of MR in muscle comes from studies in mouse models of muscular dystrophy showing that antagonizing MR activity in myotubes alters expression of known targets [17].”
BackgroundExtrarenal Effects of Aldosterone on Potassium Homeostasis
Palmer, B. F., & Clegg, D. J. (2022) · Kidney360 · doi:10.34067/kid.0006762021 · Cited by 40
Dahmana, N., Kowalczuk, L., Gabriel, D., Behar-Cohen, F., Gurny, R., & Kalia, Y. N. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00707 · Cited by 7
Metadata
- Authors
- Chadwick, J. A., Hauck, J. S., Lowe, J., Shaw, J. J., Guttridge, D. C., Gomez‐Sanchez, C. E., Gomez‐Sanchez, E. P., & Rafael‐Fortney, J. A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-07-15
- Volume
- 29
- Issue
- 11
- Pages
- 4544-4554
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1786183411
- Cited by
- 56
- References
- 7
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.